ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Androgen Receptor Degrader GSK5471713

In GlaxoSmithKline’s pipeline, AR degrader. Its studies are mostly in Prostatic Neoplasms, led by GlaxoSmithKline.

Furthest: phase 2, since Jan 9, 20261 company-led study, 1 open or runningNext primary completion: Mar 24, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline11 open or runningphase 2since Jan 9, 2026Jan 9, 2026Mar 24, 2028phase 2 · NCT07332455
  • Named in GlaxoSmithKline’s own pipeline as GSK5471713, phase 1, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 9, 2026First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT07332455 · 54 planned · United States, Australia, Canada and more

Ahead

  1. Mar 24, 2028Primary completion: phase 2 study in Prostatic NeoplasmsNCT07332455

TargetBeta

“AR degrader”the company's pipeline, read by Claude · source
“An orally bioavailable, targeted degrader of androgen receptor (AR), ”NCIt, by rule

Other programs on AR

ProgramCompanyFurthest phaseStudies
enzalutamideruleAstellas Pharmaphase 469
apalutamideruleJohnson & Johnsonphase 431
darolutamideruleBayerphase 426
Clascoteronerulecassiopea-spaphase 419
ostarinerulegtxphase 315
rezvilutamideruleJiangsu HengRui Medicinephase 313
dezandrodegruleBristol-Myers Squibbphase 35
Cyproterone AcetateruleEurofarma Laboratoriosphase 34
Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915Johnson & Johnsonphase 33
HRS-5041Jiangsu HengRui Medicinephase 26
luxdegalutamideNovartisphase 23
luxdegalutamideNovartisphase 22

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07332455Prostatic Neoplasms · United States, Australia, Canada and more2RecruitingMar 24, 202854

How it is read

Names in the registry

  • “GSK5471713”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.